By: ct2017got

02 OctGO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment


Cambridge, Mass., Oct. 2, 2018 — GO Therapeutics, Inc. (GO), a company applying new advances in glycoproteomics to develop antibody-based cancer…

Read More